Diagnosis of arrhythmogenic cardiomyopathy: The Padua criteria.
Corrado D, Perazzolo Marra M, Zorzi A, Beffagna G, Cipriani A, Lazzari M, Migliore F, Pilichou K, Rampazzo A, Rigato I, Rizzo S, Thiene G, Anastasakis A, Asimaki A, Bucciarelli-Ducci C, Haugaa KH, Marchlinski FE, Mazzanti A, McKenna WJ, Pantazis A, Pelliccia A, Schmied C, Sharma S, Wichter T, Bauce B, Basso C.
Int J Cardiol. 2020 Nov 15;319:106-114. doi: 10.1016/j.ijcard.2020.06.005. Epub 2020 Jun 16.
The Role of Contrast-Enhanced Cardiac Magnetic Resonance in the Assessment of Patients with Malignant Ventricular Arrhythmias.
Banerji D, Mendoza D, Ghoshhajra BB, Hedgire SS.
Magn Reson Imaging Clin N Am. 2019 Aug;27(3):475-490. doi: 10.1016/j.mric.2019.04.011.
Long QT Syndrome: Genetics and Future Perspective.
Wallace E, Howard L, Liu M, O'Brien T, Ward D, Shen S, Prendiville T.
Pediatr Cardiol. 2019 Oct;40(7):1419-1430. doi: 10.1007/s00246-019-02151-x. Epub 2019 Aug 22.
Electrocardiographic recognition of benign and malignant right ventricular arrhythmias.
Lee J, Adeola O, Garan H, Stevenson WG, Yarmohammadi H.
Europace. 2021 Sep 8;23(9):1338-1349. doi: 10.1093/europace/euab047.
Management of malignant ventricular arrhythmias and cardiac arrest.
Fogel RI, Prystowsky EN.
Crit Care Med. 2000 Oct;28(10 Suppl):N165-9. doi: 10.1097/00003246-200010001-00009.
[Malignant ventricular arrhythmias in patients with a right bundle-branch block and persistent ST segment elevation in V1-V3: a probable arrhythmogenic cardiomyopathy of the right ventricle].
Naccarella F.
G Ital Cardiol. 1993 Dec;23(12):1219-22.
Drug therapy versus implantation of a cardiac defibrillator for the treatment of malignant arrhythmias in left ventricular dysfunction.
Mannino MM, Mehta D, Langan NM, Gomes JA.
Am Heart J. 1996 Jun;131(6):1251-9. doi: 10.1016/s0002-8703(96)90122-2.
Clinical implications of new studies in the treatment of benign, potentially malignant and malignant ventricular arrhythmias.
Anderson JL.
Am J Cardiol. 1990 Jan 16;65(4):36B-42B. doi: 10.1016/0002-9149(90)91289-i.
Patients with malignant or potentially malignant ventricular arrhythmias: opportunities and limitations of drug therapy in prevention of sudden death.
Bigger JT Jr.
J Am Coll Cardiol. 1985 Jun;5(6 Suppl):23B-26B. doi: 10.1016/s0735-1097(85)80521-0.
The contribution of nonreentrant mechanisms to malignant ventricular arrhythmias.
Pogwizd SM, Corr B.
Basic Res Cardiol. 1992;87 Suppl 2:115-29. doi: 10.1007/978-3-642-72477-0_11.
